Revelation Biosciences, Inc.

As of October 1, 2023, Revelation Biosciences, Inc. is considered attractive due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and a 12% ROE, outperforming peers and the Sensex.

As of October 1, 2023, there is insufficient technical data for Revelation Biosciences, Inc. to determine if it is bullish or bearish.

Revelation Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $1.60 million. Key metrics include a negative P/E ratio, no dividend yield, and a debt-to-equity ratio of -1.29.

As of Jun 18, Revelation Biosciences, Inc. has a market capitalization of 1.60 million, with net sales of 0.00 million and a net profit of -14.41 million over the latest four quarters. The company's shareholder's funds are 4.71 million, and total assets are 6.62 million as of Dec 24.